ATE369385T1 - Neuer metabotropischer glutamat-rezeptor vom menschen - Google Patents

Neuer metabotropischer glutamat-rezeptor vom menschen

Info

Publication number
ATE369385T1
ATE369385T1 AT97933988T AT97933988T ATE369385T1 AT E369385 T1 ATE369385 T1 AT E369385T1 AT 97933988 T AT97933988 T AT 97933988T AT 97933988 T AT97933988 T AT 97933988T AT E369385 T1 ATE369385 T1 AT E369385T1
Authority
AT
Austria
Prior art keywords
metabotropic glutamate
glutamate receptor
mglur
human metabotropic
new human
Prior art date
Application number
AT97933988T
Other languages
German (de)
English (en)
Inventor
Thomas Stormann
Rachel Simin
Lance Hammerland
Forrest Fuller
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of ATE369385T1 publication Critical patent/ATE369385T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97933988T 1996-02-21 1997-02-20 Neuer metabotropischer glutamat-rezeptor vom menschen ATE369385T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/604,298 US6084084A (en) 1996-02-21 1996-02-21 Human metabotropic glutamate receptor

Publications (1)

Publication Number Publication Date
ATE369385T1 true ATE369385T1 (de) 2007-08-15

Family

ID=24419059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933988T ATE369385T1 (de) 1996-02-21 1997-02-20 Neuer metabotropischer glutamat-rezeptor vom menschen

Country Status (10)

Country Link
US (3) US6084084A (2)
EP (1) EP0882065B1 (2)
JP (1) JP2000506392A (2)
AT (1) ATE369385T1 (2)
AU (1) AU719841B2 (2)
CA (1) CA2246751A1 (2)
DE (1) DE69737990T2 (2)
ES (1) ES2292193T3 (2)
IL (2) IL125711A0 (2)
WO (1) WO1997048724A2 (2)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
DE69637587D1 (de) * 1995-07-26 2008-08-21 Astrazeneca Ab Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
US6221609B1 (en) * 1996-07-03 2001-04-24 Eli Lilly And Company Isolate nucleic acid encoding human MGLUR8
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
CA2325334A1 (en) * 1998-04-03 1999-10-14 Nps Pharmaceuticals, Inc. G-protein fusion receptors and chimeric gabab receptors
EP1105734A4 (en) * 1998-08-18 2005-04-13 Univ Johns Hopkins Med PROTEINS WITH INTERACTION OF THE HOMER FAMILY
EP1662255A3 (en) * 1998-08-18 2006-09-13 The Johns Hopkins University School Of Medicine Homer interacting proteins
EP1117772B1 (en) * 1998-08-31 2012-10-24 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
CA2471198A1 (en) * 2001-12-20 2003-07-03 Merck & Co., Inc. Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
AU2003207512B2 (en) * 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
WO2004050858A2 (en) * 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
WO2005073730A1 (en) * 2004-01-31 2005-08-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 8 (mglur8)
AU2005295655A1 (en) * 2004-10-14 2006-04-27 Carnegie Institution Of Washington Neurotransmitter sensors and methods of using the same
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
US8889950B2 (en) * 2006-07-28 2014-11-18 The George Washington University Repression of AtGLR3.2 increases plant biomass
US7424876B2 (en) * 2006-10-06 2008-09-16 Ford Global Technologies, Llc Pushrod engine with multiple independent lash adjusters for each pushrod
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
WO2009079566A2 (en) * 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
EP2910637A1 (en) * 2008-05-20 2015-08-26 University of Florida Research Foundation, Inc. Vectors for delivery of light-sensitive proteins and methods of use
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1311829A (en) * 1971-02-20 1973-03-28 Hayashibara Co Sealsoning of comestibles
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5177011A (en) * 1988-08-18 1993-01-05 Calgene, Inc. Plant elongation factor promoters, coding sequences and uses
JP2944721B2 (ja) * 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
RU2147574C1 (ru) * 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения
CN1192011C (zh) * 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
EP0642589A4 (en) * 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
ATE283916T1 (de) * 1993-09-20 2004-12-15 Novartis Pharma Gmbh Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
US6274330B1 (en) * 1993-12-30 2001-08-14 Zymogenetics, Inc. L-AP4 sensitive glutamate receptors
EP0759978A4 (en) * 1994-05-16 1997-12-29 Human Genome Sciences Inc CARRIER PROTEIN FOR NEW TRANSMITTERS
DE69637587D1 (de) * 1995-07-26 2008-08-21 Astrazeneca Ab Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Also Published As

Publication number Publication date
DE69737990D1 (de) 2007-09-20
AU719841B2 (en) 2000-05-18
US6051688A (en) 2000-04-18
EP0882065A2 (en) 1998-12-09
IL125711A (en) 2006-09-05
AU3715697A (en) 1998-01-07
WO1997048724A3 (en) 1998-03-26
ES2292193T3 (es) 2008-03-01
JP2000506392A (ja) 2000-05-30
IL125711A0 (en) 1999-04-11
EP0882065B1 (en) 2007-08-08
CA2246751A1 (en) 1997-12-24
US6084084A (en) 2000-07-04
DE69737990T2 (de) 2008-09-11
WO1997048724A2 (en) 1997-12-24
US6077675A (en) 2000-06-20

Similar Documents

Publication Publication Date Title
ATE369385T1 (de) Neuer metabotropischer glutamat-rezeptor vom menschen
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
CY1113355T1 (el) Χρηση θεραπειας νευροτοξινης για θεραπευτικη αγωγη ουρολογικων και σχετικων διαταραχων
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE403672T1 (de) Oral aktive fraktion der momordica charantia, ihre aktiven peptide und ihre verwendung bei der behandlung des diabetes
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
NO20000396D0 (no) Katalytiske monoklonale antistoffer med protease-aktivitet for selektiv lysis av proteinkomponenten hos plakker og aggregater relatert til patologiske tilstander
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
EP0921785A4 (en) COMBINATION OF ACID PROTEASE ENZYMS AND ACID BUFFERS AND THEIR USE
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE500328T1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
EP0322226A3 (en) Site-directed mutagenesis modified glycoprotein hormones and methods of use
ATE135916T1 (de) Hirnaktivitätfördernde zubereitungen
ATE331531T1 (de) Lösliche lymphotoxin-beta rezeptoren, anti- lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
FR2569697B1 (fr) Produits derives de la mitomycine et leur application au traitement de maladies neoplasiques
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
ATE216589T1 (de) Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
NO994630D0 (no) Metoder for behandling av vaskulaere sykdommer
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties